Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Research at Oxford on Analysis of Motion (ROAM) team at the University of Oxford have supported CURE Ethiopia Children’s Hospital to develop and open a brand new gait laboratory, the first of its kind in the country and the only other active gait lab on the African continent outside of South Africa.

Gait lab doctors with a patient
Image - CURE International

A gait lab uses special motion-capture cameras (the same type of cameras used for making animated movies and computer games) to track a patient’s movement. In the lab, reflective markers are placed all over the patient’s body. The cameras emit light, and when that light is reflected via the reflective markers, the camera follows its movement, thereby recording the joint motion tracking the patient’s movement. In addition to the cameras, the patient also walks on sensitive plates that provide further information. The innovative technology is primarily used for patients with neuromuscular disorders (like cerebral palsy) to analyse their walking and to help determine the ideal treatment for the patient. 

Dr Tim Nunn, Consultant Orthopaedic Surgeon at CURE Ethiopia, said: “Since the gait lab opened, we have been able to assess over 40 patients for severe cerebral palsy conditions. Many of these patients have been discussed with our collaborating team at the Gait Laboratory in Oxford. It has helped us to accurately plan the optimal surgery to achieve the greatest benefit to each patient.”

Image - CURE International Image - CURE International

The gait lab equipment was donated to CURE Ethiopia by three different companies (VICON, AMTI, and NOVEL) coordinated by the ROAM team based at Nuffield Department of Orthopaedics and Rheumatology and Musculoskeletal Sciences at the University of Oxford. Mr. Tim Theologis, a paediatric orthopaedic surgeon and specialist in cerebral palsy from Oxford, has been integral to the project. Dr. Julie Stebbins, an international authority on gait analysis, came to install the equipment and train doctors and physicians in 2019. Dr. Stebbins, who completed her doctorate in bioengineering and biomedical engineering, works in Oxford’s Gait Laboratory at Oxford University Hospitals NHS Foundation Trust.

Dr Stebbins said: “I do the clinical part of the research. We mostly see children who have problems walking, and we measure their gait with the cameras to help find treatment options for them.” 

The Clinical Movement Analysis Society of UK and Ireland recently awarded funding towards this health partnership and Dr Julie Stebbins will visit CURE Ethiopia Children’s Hospital to continue with training and help set up a joint research program. 

Similar stories

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?